drugset / Trial / NCT05841992
Al18F-PSMA-617 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients
NaSingle-groupOpen-labelDiagnostic
Summary
18F-labeled prostate-specific membrane antigen (PSMA) ligand-positron emission tomography (PET) offers advantages over 68Ga-labeled PSMA ligands. Al18F-PSMA-617 is a novel 18F-PSMA compound used for prostate cancer (PCa) imaging. This pilot study was prospectively designed to compare the lesion detectability of Al18F-PSMA-617 and related 68Ga-PSMA-617 PET/CT in patients with PCa
Timeline
- Start
- 2021-07-01
- Primary completion
- 2023-05-01
- Completion
- 2023-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Al18F-PSMA-617 | Diagnostic / imaging agent | 0.1 unknown | Intravenous |
| Subject | VIPIVOTIDE TETRAXETAN GALLIUM | Diagnostic / imaging agent | 148 mbq | Intravenous |
| Subject | VIPIVOTIDE TETRAXETAN GALLIUM | Diagnostic / imaging agent | 185 mbq | Intravenous |